IDO1 and non-small cell lung carcinoma: Hence, we initiated a phase I vaccination study, which is ongoing (from June 2010) at Center for Caner Immune Therapy, Copenhagen University Hospital, Herlev, in which patients with non-small cell lung cancer (NSCLC) are vaccinated with a IDO-derived peptide with Montanide adjuvant (www.clinicaltrials.gov; NCT01219348).